WEBCASTS
Investing in Weight Loss and Preventative Healthcare
42% of U.S. adults and over 1 billion people worldwide are clinically obese.1 The GLP-1 market is expected to grow 21x to $130 billion by 2030.2 Consequently, the breakthrough weight loss GLP-1 technology could have shockingly large implications and create opportunities for savvy investors.
Join the experts at Amplify ETFs and learn how GLP-1's could revolutionize the weight loss drug market as well as a strategy that can give your portfolio exposure to a theme that could see significant growth in the coming years.
SUMMARY
Topics covered will include:
- The current weight loss drug landscape and tailwinds.
- What GLP-1 technology is and why it matters.
- A strategy that provides exposure to the weight loss theme.
This program has been approved for one hour of continuing education (CE) credit by the Certified Financial Planner Board of Standards for the CFP® designation, The Investment and Wealth Institute for CIMA®, CPWA®, and RMA® designations and The American College of Financial Services.
CFA Institute members are encouraged to self-document their continuing professional development activities in their online CE tracker.
SPEAKERS
Christian Magoon
Founder & CEOAmplify ETFs
Jane Edmondson
Head of Thematic StrategyVettaFi
Cinthia Murphy
Investment StrategistVettaFi
Disclaimer
By registering, you are certifying that you are a financial professional and agree to share your data with VettaFi and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to VettaFi's Privacy Policy. You can unsubscribe at any time.
Important Disclosures
Carefully consider the Fund’s investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund’s statutory and summary prospectuses, which may be obtained at AmplifyETFs.com. Read the prospectus carefully before investing.
Investing involves risk, including the possible loss of principal. There can be no assurance that the Fund’s investment objectives will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. The Fund invests in securities included in its Index regardless of their investment merit and may experience tracking error: the differences in timing of trades, valuation, plus fees and expenses between fund and index.
A non-diversified fund can invest a greater portion of its assets in securities of individual issuers which could cause greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition.
Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments. Investments in foreign securities, especially in emerging markets, involve greater volatility and political, economic, and currency risks and differences in accounting methods beyond those of securities of U.S. issuers.
Amplify Investments LLC serves as the investment adviser to the Fund. Penserra Capital Management LLC serves as the investment sub advisor to the fund. Amplify ETFs are distributed by Foreside Fund Services, LLC.
1World Health Organization, One in Eight People Are Now Living with Obesity, 03/2024. Pew Research Center, As Obesity Rates Rise in the US and Worldwide, New Weight Loss Drugs Surge in Popularity, 03/2024.
2Goldman Sachs, Anti-Obesity Drug Market. 10/2023. | https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate